203 related articles for article (PubMed ID: 20208386)
1. System-dependent outcomes during the evaluation of drug candidates as inhibitors of cytochrome P450 (CYP) and uridine diphosphate glucuronosyltransferase (UGT) enzymes: human hepatocytes versus liver microsomes versus recombinant enzymes.
Parkinson A; Kazmi F; Buckley DB; Yerino P; Ogilvie BW; Paris BL
Drug Metab Pharmacokinet; 2010; 25(1):16-27. PubMed ID: 20208386
[TBL] [Abstract][Full Text] [Related]
2. In vitro inhibition of human liver cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT) enzymes by rose bengal: system-dependent effects on inhibitory potential.
Kazmi F; Haupt LJ; Horkman JR; Smith BD; Buckley DB; Wachter EA; Singer JM
Xenobiotica; 2014 Jul; 44(7):606-14. PubMed ID: 24405273
[TBL] [Abstract][Full Text] [Related]
3. Hydroxychloroquine is Metabolized by Cytochrome P450 2D6, 3A4, and 2C8, and Inhibits Cytochrome P450 2D6, while its Metabolites also Inhibit Cytochrome P450 3A
Paludetto MN; Kurkela M; Kahma H; Backman JT; Niemi M; Filppula AM
Drug Metab Dispos; 2023 Mar; 51(3):293-305. PubMed ID: 36446607
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of cytochrome P450 enzymes and uridine 5'-diphospho-glucuronosyltransferases by vicagrel in human liver microsomes: A prediction of potential drug-drug interactions.
Liu S; Wang Z; Chan E; Zhao Y; Kang J; Zhang X; Tian X
Chem Biol Interact; 2022 Jan; 352():109775. PubMed ID: 34910929
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory Effects of Aschantin on Cytochrome P450 and Uridine 5'-diphospho-glucuronosyltransferase Enzyme Activities in Human Liver Microsomes.
Kwon SS; Kim JH; Jeong HU; Cho YY; Oh SR; Lee HS
Molecules; 2016 Apr; 21(5):. PubMed ID: 27128896
[TBL] [Abstract][Full Text] [Related]
6. Direct comparison of UDP-glucuronosyltransferase and cytochrome P450 activities in human liver microsomes, plated and suspended primary human hepatocytes from five liver donors.
den Braver-Sewradj SP; den Braver MW; Baze A; Decorde J; Fonsi M; Bachellier P; Vermeulen NPE; Commandeur JNM; Richert L; Vos JC
Eur J Pharm Sci; 2017 Nov; 109():96-110. PubMed ID: 28778465
[TBL] [Abstract][Full Text] [Related]
7. In Vitro Characterization of Ertugliflozin Metabolism by UDP-Glucuronosyltransferase and Cytochrome P450 Enzymes.
Lapham K; Callegari E; Cianfrogna J; Lin J; Niosi M; Orozco CC; Sharma R; Goosen TC
Drug Metab Dispos; 2020 Dec; 48(12):1350-1363. PubMed ID: 33020067
[TBL] [Abstract][Full Text] [Related]
8. Drug-drug interactions in the metabolism of imidafenacin: role of the human cytochrome P450 enzymes and UDP-glucuronic acid transferases, and potential of imidafenacin to inhibit human cytochrome P450 enzymes.
Kanayama N; Kanari C; Masuda Y; Ohmori S; Ooie T
Xenobiotica; 2007 Feb; 37(2):139-54. PubMed ID: 17484517
[TBL] [Abstract][Full Text] [Related]
9. Comparison of inhibition potentials of drugs against zidovudine glucuronidation in rat hepatocytes and liver microsomes.
Mano Y; Usui T; Kamimura H
Drug Metab Dispos; 2007 Apr; 35(4):602-6. PubMed ID: 17267620
[TBL] [Abstract][Full Text] [Related]
10. AM-2201 Inhibits Multiple Cytochrome P450 and Uridine 5'-Diphospho-Glucuronosyltransferase Enzyme Activities in Human Liver Microsomes.
Kim JH; Kwon SS; Kong TY; Cheong JC; Kim HS; In MK; Lee HS
Molecules; 2017 Mar; 22(3):. PubMed ID: 28287454
[TBL] [Abstract][Full Text] [Related]
11. Predictive In Vitro-In Vivo Extrapolation for Time Dependent Inhibition of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and CYP2D6 Using Pooled Human Hepatocytes, Human Liver Microsomes, and a Simple Mechanistic Static Model.
Ramsden D; Perloff ES; Whitcher-Johnstone A; Ho T; Patel R; Kozminski KD; Fullenwider CL; Zhang JG
Drug Metab Dispos; 2022 Feb; 50(2):114-127. PubMed ID: 34789487
[TBL] [Abstract][Full Text] [Related]
12. Metabolic interactions of rosmarinic acid with human cytochrome P450 monooxygenases and uridine diphosphate glucuronosyltransferases.
Kim SB; Kim KS; Kim DD; Yoon IS
Biomed Pharmacother; 2019 Feb; 110():111-117. PubMed ID: 30466000
[TBL] [Abstract][Full Text] [Related]
13. Further Characterization of the Metabolism of Desloratadine and Its Cytochrome P450 and UDP-glucuronosyltransferase Inhibition Potential: Identification of Desloratadine as a Relatively Selective UGT2B10 Inhibitor.
Kazmi F; Yerino P; Barbara JE; Parkinson A
Drug Metab Dispos; 2015 Sep; 43(9):1294-302. PubMed ID: 26135009
[TBL] [Abstract][Full Text] [Related]
14. Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.
Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2005 Oct; 97(4):249-56. PubMed ID: 16176562
[TBL] [Abstract][Full Text] [Related]
15. Charactering the metabolism of cryptotanshinone by human P450 enzymes and uridine diphosphate glucuronosyltransferases in vitro.
Zeng J; Fan YJ; Tan B; Su HZ; Li Y; Zhang LL; Jiang J; Qiu FR
Acta Pharmacol Sin; 2018 Aug; 39(8):1393-1404. PubMed ID: 29417949
[TBL] [Abstract][Full Text] [Related]
16. [Investigation of metabolic kinetics and reaction phenotyping of ligustrazin by using liver microsomes and recombinant human enzymes].
Tan Y; Zhuang XM; Shen GL; Li H; Gao Y
Yao Xue Xue Bao; 2014 Mar; 49(3):374-9. PubMed ID: 24961110
[TBL] [Abstract][Full Text] [Related]
17. A long-standing mystery solved: the formation of 3-hydroxydesloratadine is catalyzed by CYP2C8 but prior glucuronidation of desloratadine by UDP-glucuronosyltransferase 2B10 is an obligatory requirement.
Kazmi F; Barbara JE; Yerino P; Parkinson A
Drug Metab Dispos; 2015 Apr; 43(4):523-33. PubMed ID: 25595597
[TBL] [Abstract][Full Text] [Related]
18. In vitro metabolism of eupatilin by multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes.
Lee HS; Ji HY; Park EJ; Kim SY
Xenobiotica; 2007 Aug; 37(8):803-17. PubMed ID: 17701830
[TBL] [Abstract][Full Text] [Related]
19. In vitro characterization of the metabolic pathways and cytochrome P450 inhibition and induction potential of BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor.
Hong H; Su H; Ma L; Yao M; Iyer RA; Humphreys WG; Christopher LJ
Drug Metab Dispos; 2011 Sep; 39(9):1658-67. PubMed ID: 21673131
[TBL] [Abstract][Full Text] [Related]
20. Metabolism and related human risk factors for hepatic damage by usnic acid containing nutritional supplements.
Foti RS; Dickmann LJ; Davis JA; Greene RJ; Hill JJ; Howard ML; Pearson JT; Rock DA; Tay JC; Wahlstrom JL; Slatter JG
Xenobiotica; 2008 Mar; 38(3):264-80. PubMed ID: 18274956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
